Amylin gets FDA OK for weekly diabetes drug Bydureon

Say hello to Bydureon, a once-weekly injectable treatment for Type 2 diabetes finally approved by the FDA on Jan. 27. Amylin Pharmaceuticals ($AMLN) developed the drug using controlled release drug delivery technology supplied by Alkermes ($ALKS). Amylin is billing the drug as the "first and only" weekly Type 2 diabetes treatment approved to date by the FDA, versus the standard twice-daily injections. Bydureon consists of biodegradable microspheres, which release a controlled amount of the drug over 7 days. Regulators previously rejected Bydureon twice before. Release | Story

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.